|
Boehringer Presents New Phase III Data for Asthma Therapy Tiotropium
Lung Disease News Boehringer Ingelheim Pharmaceutical company Boehringer Ingelheim recently presented encouraging data regarding its investigational drug tiotropium delivered through the company's Respimat inhaler, for the treatment of asthma. The data was presented … Tiotropium improves lung function in asthma, regardless of allergic status |
View full post on asthma – Google News